Medicus Pharma (MDCX) announced that the SKNJCT-004 phase 2 clinical study, to non-invasively treat BCC of the skin, has commenced patient recruitment in Cleveland clinic Abu Dhabi. Earlier this year, in May 2025, SKNJCT-004 received “study may proceed” approval from the UAE Department of Health. The study is expected to randomize thirty-six patients in four sites in UAE. In addition to Cleveland Clinic Abu Dhabi, the study is also expected to commence patient recruitment in Sheikh Shakbout Medical City, Burjeel Medical City, Rashid Hospital, Clemenceau Medical Center and American Hospital of Dubai. Insights Research Organization and Solutions, a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDCX:
- Medicus Pharma Ltd. Acquires Antev Limited, Expanding Drug Development Pipeline
- Medicus Pharma Completes Equity Sales to Yorkville
- Medicus Pharma Advances D-MNA Clinical Program and Expands Strategic Partnerships
- Medicus Pharma and HelixNano Announce Vaccine Collaboration
- Medicus Pharma Appoints Deloitte for Licensing Deal